Literature DB >> 21833619

High level expression of recombinant BoNT/A-Hc by high cell density cultivation of Escherichia coli.

Kheirollah Yari1, Seyed Safa-Ali Fatemi, Mahmood Tavallaei.   

Abstract

The carboxylic domain of the Clostridium botulinum neurotoxin heavy chain (BoNT/A-HC), which has been reported as a vaccine candidate, contains the principle protective antigenic determinants. In this study, the high level expression of the BoNT/A-Hc was achieved by high cell density cultivation of recombinant Escherichia coli in a 2-l batch stirred-tank bioreactor. In order to maximize protein expression, post-induction time and IPTG inducer concentration were optimized by the Taguchi statistical design method. Results showed that the middle of the logarithmic phase and an IPTG concentration of 1 mM presented the optimum conditions for the maximum expression of BoNT/A-HC. High cell density cultivation was subsequently carried out as an effective strategy for the high level expression of recombinant BoNT/A-Hc. Consequently, soluble BoNT/A-Hc was produced at the maximum level of 486 mg l(-1), at 3 h post-induction, which was approximately 9.3 and 7.8 times higher than the levels produced by the shake flask and batch culturing methods, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833619     DOI: 10.1007/s00449-011-0579-y

Source DB:  PubMed          Journal:  Bioprocess Biosyst Eng        ISSN: 1615-7591            Impact factor:   3.210


  9 in total

Review 1.  Stepwise optimization of recombinant protein production in Escherichia coli utilizing computational and experimental approaches.

Authors:  Kulandai Arockia Rajesh Packiam; Ramakrishnan Nagasundara Ramanan; Chien Wei Ooi; Lakshminarasimhan Krishnaswamy; Beng Ti Tey
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-19       Impact factor: 4.813

2.  Molecular cloning, expression and purification of recombinant soluble mouse endostatin as an anti-angiogenic protein in Escherichia coli.

Authors:  Kheirollah Yari; Saboor Afzali; Hadi Mozafari; Kamran Mansouri; Ali Mostafaie
Journal:  Mol Biol Rep       Date:  2012-10-17       Impact factor: 2.316

3.  Production and purification of the multifunctional enzyme horseradish peroxidase.

Authors:  Oliver Spadiut; Christoph Herwig
Journal:  Pharm Bioprocess       Date:  2013-08-01

4.  Analysis of Methods to Improve the Solubility of Recombinant Bovine Sex Determining Region Y Protein.

Authors:  Bijan Soleymani; Ali Mostafaie
Journal:  Rep Biochem Mol Biol       Date:  2019-10

5.  Optimization of rPDT fusion protein expression by Escherichia coli in pilot scale fermentation: a statistical experimental design approach.

Authors:  Nasser Nassiri Koopaei; Parissa Khadiv-Parsi; Mohammad Reza Khoshayand; Mohammad Ali Mazlomi; Abbas Kebriaeezadeh; Hamid Moloudian; Roya Solhi; Mahdi Aminian
Journal:  AMB Express       Date:  2018-08-22       Impact factor: 3.298

6.  Expression of full and fragment-B of diphtheria toxin genes in Escherichia coli for generating of recombinant diphtheria vaccines.

Authors:  Shaimaa Abulmagd; Abd El-Nasser A Khattab; Hamdallah Zedan
Journal:  Clin Exp Vaccine Res       Date:  2022-01-31

Review 7.  Strategies for efficient production of recombinant proteins in Escherichia coli: alleviating the host burden and enhancing protein activity.

Authors:  Zi-Xu Zhang; Fang-Tong Nong; Yu-Zhou Wang; Chun-Xiao Yan; Yang Gu; Ping Song; Xiao-Man Sun
Journal:  Microb Cell Fact       Date:  2022-09-15       Impact factor: 6.352

Review 8.  Major pathogenic Clostridia in human and progress toward the clostridial vaccines.

Authors:  Lida Abdolmohammadi Khiav; Azadeh Zahmatkesh
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

9.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.